- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04206852
Segurança e eficácia da angioplastia pulmonar com balão na China
Balloon pulmonary angioplasty (BPA) is a potential treatment for patients with pulmonary artery stenosis, including non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH), takayasu arteritis and fibrosis mediastinitis.
The aim of this study was to evaluate the safety and efficacy of BPA in CTEPH and patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA, , takayasu arteritis and fibrosis mediastinitis.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This study is a prospective, multi-center, long-term observational project to study the safety and efficacy of BPA. Clinical evaluation, including: functional capacity, 6-minutes walking test, biomarkers, cardiopulmonary exercise test, electrocardiography, echocardiography, haemodynamics, pulmonary angiography and lung scintigraphy was performed before the initiation therapy of BPA, and 3-12 months after last session of BPA.
we also aim to evaluate the value of FAPI in predicting the efficacy and the prognosis of patients with CTEPH who received BPA.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Zhihong Liu, doctor
- Número de telefone: 8601088396985
- E-mail: zhihongliufuwai@163.com
Locais de estudo
-
-
-
Beijing, China, 100037
- Recrutamento
- center of pulmonary vascular disease, Fuwai hospital
-
Contato:
- Zhihong Liu, doctor
- Número de telefone: 8601088396816
- E-mail: zhihongliufuwai@163.com
-
Investigador principal:
- Zhihong Liu, MD,PhD
-
Beijing, China, 100037
- Recrutamento
- Chinese Academy of Medical Sciences Fuwai hospital
-
Contato:
- Zhao zhihui, MD
- Número de telefone: 8615810348817
- E-mail: 1250167892@qq.com
-
Contato:
- Yang Tao, MD
- Número de telefone: 8618610358576
- E-mail: tsmcyt@163.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Chronic thromboembolic pulmonary hypertension patients admitted in hospital.
Descrição
Inclusion Criteria:
- diagnosed with CTEPH according to ESC Guidelines (1) Mean PAP ≥ 25mmHg at rest; or if mean PAP < 25mmHg at rest, have exercise limitations from chronic thromboembolic disease (2)Abnormal ventilation perfusion lung scanning (VQ) scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines
- Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH
- Not amenable to pulmonary endarterectomy
- Willing to provide informed consent
Exclusion Criteria:
- Patients unwilling or unable to provide written consent for participation in the study.
- Impossible to follow up.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events of BPA procedure.
Prazo: From initiation of BPA to 3-12 months after last session
|
Surveillance of complications including: vessel injury, desaturation, cough, mild hemoptysis (<50ml), severe hemoptysis (>50ml), reperfusion pulmonary injury, death. |
From initiation of BPA to 3-12 months after last session
|
|
Change of Pulmonary artery pressure in mmHg caused by series of BPA.
Prazo: From initiation of BPA to 3-12 months after last session
|
Pulmonary artery pressure in mmHg is obtained by right cardiac catheterization. |
From initiation of BPA to 3-12 months after last session
|
|
Change of Pulmonary vascular resistance (PVR) in Wood U caused by series of BPA.
Prazo: From initiation of BPA to 3-12 months after last session
|
Pulmonary vascular resistance (PVR) in Wood U is obtained by right cardiac catheterization. |
From initiation of BPA to 3-12 months after last session
|
|
Change of cardiac index (CI) in L/m^2 caused by series of BPA.
Prazo: From initiation of BPA to 3-12 months after last session
|
Cardiac index (CI) in L/m^2 is obtained by right cardiac catheterization. |
From initiation of BPA to 3-12 months after last session
|
|
Change of World Health Organization (WHO) functional capacity classification caused by series of BPA.
Prazo: From initiation of BPA to 3-12 months after last session
|
World Health Organization is obtained from electronic medical records. |
From initiation of BPA to 3-12 months after last session
|
|
Change of six minutes walk distance in meter caused by series of BPA.
Prazo: From initiation of BPA to 3-12 months after last session
|
World Health Organization is obtained from electronic medical records. |
From initiation of BPA to 3-12 months after last session
|
|
Change of N-terminal B-type natriuretic peptide in pg/ml caused by series of BPA.
Prazo: From initiation of BPA to 3-12 months after last session
|
World Health Organization is obtained from electronic medical records. |
From initiation of BPA to 3-12 months after last session
|
|
Change of Peak VO2/kg in ml/min/kg caused by series of BPA.
Prazo: From initiation of BPA to 3-12 months after last session
|
Peak VO2/kg in ml/min/kg is obtained by cardiopulmonary exercise test. |
From initiation of BPA to 3-12 months after last session
|
|
Change of diffusing capacity for carbon monoxide caused by series of BPA.
Prazo: From initiation of BPA to 3-12 months after last session
|
diffusing capacity for carbon monoxide in % is obtained from pulmonary function test |
From initiation of BPA to 3-12 months after last session
|
|
Change of fibroblast activation protein inhibitor expression after BPA
Prazo: From initiation of BPA to 3-12 months after last session
|
Change of fibroblast activation protein inhibitor expression after BPA |
From initiation of BPA to 3-12 months after last session
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças Vasculares
- Doenças cardiovasculares
- Doenças Respiratórias
- Doenças de pele
- Doenças de Pele, Vasculares
- Doenças Arteriais Oclusivas
- Doenças da Aorta
- Vasculite
- Arterite
- Doenças do Mediastino
- Doenças Torácicas
- Doenças da Pele e do Tecido Conjuntivo
- Síndromes do Arco Aórtico
- Estenose, Artéria Pulmonar
- Arterite de Takayasu
- Mediastinite
Outros números de identificação do estudo
- BPA registry
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .